Experience
Cerberus Announces Landmark Investment in Aquatech
April 3, 2025
Cooley advised Cerberus Capital Management, a global leader in alternative investing with approximately $65 billion in assets across complementary credit, real estate and private equity strategies, on its growth investment in Aquatech, a global leader in water technology and services for industrial and infrastructure markets.
Related contacts
Related Practices & Industries
Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors
Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors
November 7, 2024
Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.
Related contacts
Related Practices & Industries
Battery Ventures-Backed PageUp To Be Acquired by EQT Partners
October 31, 2024
Cooley advised Battery Ventures, a global, technology-focused investment firm, and PageUp Group, a human resources and talent software company that had been majority owned by Battery, on the sale of PageUp to EQT Group.
Related contacts
Related Practices & Industries
Cooley Advises Uber on $5 Billion Investment-Grade Revolving Credit Facility
October 2, 2024
Cooley advised Uber Technologies on its $5 billion investment-grade revolving credit facility.
Related contacts
Related Practices & Industries
Snowflake Announces $2.3 Billion Convertible Senior Notes Offering
September 27, 2024
Cooley advised Snowflake, the artificial intelligence (AI) Data Cloud company, on its private placement of $2.3 billion aggregate principal amount of convertible senior notes, consisting of $1.15 billion principal amount of convertible senior notes due 2027 and $1.15 billion aggregate principal amount of convertible senior notes due 2029, which includes the exercise in full of the initial purchasers’ options to purchase an additional $150 million principal amount of 2027 notes and $150 million principal amount of 2029 notes.
Related contacts
Related Practices & Industries
Related news and events
Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors
Admissions and credentials
California